Abbreviated Name

PASS: Ref Set App: Cooperberg miRNA (2018)

Lead Investigator

Carroll, Peter R. — University of California San Francisco

Coordinating Investigator

No coordinating investigator

Involved Investigators

• Carroll, Peter R. — University of California San Francisco

Abstact

No abstract availalbe.

Aims

The objective of this aim is to leverage
this remarkable resource to follow
plasma miRNAs during the course of
observation. In PASS, plasma samples
have been collected every 6 months for the whole cohort. We hypothesize that we will be able to validate the miRNA signature at diagnosis and/or during the course of AS to predict disease course and thus identify the subset of patients that will eventually show clear disease progression. To explore this hypothesis, we will measure miRNAs in semiannual plasma specimens over a 2.5 year period. To our knowledge, this study would be the first time in any cancer where consecutive miRNA measurements are made to follow a disease course. The rationale for performing such a study is that successful identification of a signature could alter treatment course. One exciting possibility is that such a signature could allow the intensity of surveillance to be customized, specifically allowing many men to minimize the frequency of follow-up via invasive and expensive biopsies. Conversely, earlier detection of progression could lead to intervention before the disease becomes incurable.

Analytic Method

No analytic method available.

Comments

Cooperberg is the actual PI

Publications

• No publications available at this time for this protocol.

Biomarkers

• No biomarkers available at this time for this protocol.

Data Collections

• No data collections available at this time for this protocol.

 Team Project

Protocol ID

445

Protocol Type

Reference Set

Field of Research

Epigenomics

Collaborative Group

Prostate and Urologic Cancers Research Group

Cancer Types

• Malignant neoplasm of prostate

Phased Status

2